Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.
Kato D, Suzuki T, Matsuura K, Okayama K, Okumura F, Nagura Y, Sobue S, Hayashi K, Kusakabe A, Hasegawa I, Matoya S, Mizoshita T, Kimura Y, Kondo H, Ozasa A, Kawamura H, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Kato D, et al. Among authors: nojiri s. Oncology. 2024 Oct 18:1-9. doi: 10.1159/000541455. Online ahead of print. Oncology. 2024. PMID: 39427645
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Matoya S, et al. Among authors: nojiri s. Hepatol Res. 2023 Jun;53(6):511-521. doi: 10.1111/hepr.13886. Epub 2023 Feb 18. Hepatol Res. 2023. PMID: 36723964
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Kuroyanagi K, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Suzuki T, et al. Among authors: nojiri s. Cancer Med. 2024 Jan;13(1):e6876. doi: 10.1002/cam4.6876. Epub 2023 Dec 22. Cancer Med. 2024. PMID: 38133557 Free PMC article.
Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kato D, Kusakabe A, Koguchi H, Hasegawa I, Matoya S, Miyaki T, Kimura Y, Tanaka Y, Kondo H, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group. Suzuki T, et al. Among authors: nojiri s. Oncology. 2024;102(8):676-687. doi: 10.1159/000536367. Epub 2024 Jan 18. Oncology. 2024. PMID: 38237558
Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Murakami S, Inoue T, Kuroyanagi K, Kawamura H, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Suzuki T, et al. Among authors: nojiri s. J Gastroenterol Hepatol. 2024 Oct;39(10):2158-2168. doi: 10.1111/jgh.16672. Epub 2024 Jun 28. J Gastroenterol Hepatol. 2024. PMID: 38943340
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Suzuki T, et al. Among authors: nojiri s. Hepatol Res. 2023 Apr;53(4):289-300. doi: 10.1111/hepr.13864. Epub 2022 Dec 16. Hepatol Res. 2023. PMID: 36461885
302 results